Guggenheim Capital LLC Decreases Stake in Twist Bioscience Co. (NASDAQ:TWST)

Guggenheim Capital LLC decreased its holdings in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 31.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 19,065 shares of the company's stock after selling 8,645 shares during the quarter. Guggenheim Capital LLC's holdings in Twist Bioscience were worth $886,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Thrivent Financial for Lutherans lifted its holdings in shares of Twist Bioscience by 54.6% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company's stock valued at $69,972,000 after purchasing an additional 532,040 shares in the last quarter. Jennison Associates LLC boosted its holdings in Twist Bioscience by 80.2% during the 4th quarter. Jennison Associates LLC now owns 680,778 shares of the company's stock worth $31,636,000 after acquiring an additional 302,884 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of Twist Bioscience by 63.5% in the fourth quarter. American Century Companies Inc. now owns 756,352 shares of the company's stock valued at $35,148,000 after purchasing an additional 293,751 shares during the last quarter. ARK Investment Management LLC lifted its position in shares of Twist Bioscience by 4.4% during the fourth quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company's stock valued at $260,040,000 after purchasing an additional 237,772 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Twist Bioscience by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock worth $269,860,000 after purchasing an additional 189,791 shares during the last quarter.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, Director Robert Chess sold 2,940 shares of the firm's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $53.13, for a total value of $156,202.20. Following the completion of the sale, the director now directly owns 18,173 shares in the company, valued at $965,531.49. This trade represents a 13.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Paula Green sold 1,259 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $62,131.65. Following the completion of the transaction, the senior vice president now directly owns 132,014 shares of the company's stock, valued at $6,514,890.90. This represents a 0.94 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 22,432 shares of company stock worth $1,038,170 in the last three months. 3.01% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

TWST has been the subject of several recent analyst reports. Guggenheim set a $50.00 target price on Twist Bioscience in a report on Friday, March 28th. Robert W. Baird lifted their target price on Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 4th. JPMorgan Chase & Co. raised their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a report on Tuesday, February 4th. Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Finally, Barclays decreased their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Twist Bioscience presently has a consensus rating of "Moderate Buy" and a consensus price target of $52.80.

Twist Bioscience Price Performance

Shares of TWST traded down $0.93 during midday trading on Tuesday, hitting $38.97. 66,665 shares of the company traded hands, compared to its average volume of 976,515. Twist Bioscience Co. has a one year low of $30.32 and a one year high of $60.90. The firm has a market cap of $2.32 billion, a P/E ratio of -11.49 and a beta of 2.34. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. The stock has a 50-day moving average of $39.51 and a 200-day moving average of $44.26.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm's revenue was up 24.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.75) earnings per share. As a group, sell-side analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.